Emergence and geographic dominance of Omicron subvariants XBB/XBB.1.5 and BF.7 - the public health challenges

Thirumalaisamy P Velavan, Francine Ntoumi, Peter G Kremsner, Shui Shan Lee, Christian G Meyer, Thirumalaisamy P Velavan, Francine Ntoumi, Peter G Kremsner, Shui Shan Lee, Christian G Meyer

No abstract available

Keywords: BF.7; China; Epidemiology; Europe; Immune evasion; Omicron; Public Health; XBB.1.5; Zero COVID; variants.

Conflict of interest statement

Declaration of Competing Interest The authors declare that they have no conflict of interest.

References

    1. Petersen E, Ntoumi F, Hui DS, Abubakar A, Kramer LD, Obiero C, et al. Emergence of new SARS-CoV-2 Variant of Concern Omicron (B.1.1.529) - highlights Africa's research capabilities, but exposes major knowledge gaps, inequities of vaccine distribution, inadequacies in global COVID-19 response and control efforts. Int J Infect Dis. 2022;114:268–272. doi: 10.1016/j.ijid.2021.11.040.
    1. WHO: TAG-VE statement on Omicron sublineages BQ.1 and XBB. In: World Health organization. 2022.
    1. Tallei TE, Alhumaid S, AlMusa Z, Fatimawali Kusumawaty D, Alynbiawi A, et al. Update on the omicron sub-variants BA.4 and BA.5. Rev Med Virol. 2022:e2391. doi: 10.1002/rmv.2391.
    1. WHO: Tracking SARS-CoV-2 variants. World Health Organization. 2022
    1. Zhang X, Chen LL, Ip JD, Chan WM, Hung IF, Yuen KY, et al. Omicron sublineage recombinant XBB evades neutralising antibodies in recipients of BNT162b2 or CoronaVac vaccines. Lancet Microbe. 2022 doi: 10.1016/S2666-5247(22)00335-4.
    1. ECDC: Update on SARS-CoV-2 variants: ECDC assessment of the XBB.1.5 sub-lineage. European Centre for Disease Prevention and Control. 2023
    1. Wang Q, Iketani S, Li Z, Liu L, Guo Y, Huang Y, et al. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. Cell. 2022 doi: 10.1016/j.cell.2022.12.018.
    1. Yue C, Song W, Wang L, Jian F, Chen X, Gao F, et al. Enhanced transmissibility of XBB.1.5 is contributed by both strong ACE2 binding and antibody evasion. bioRxiv. 2023:2023.01.03.522427; doi:10.1101/2023.01.03.522427.
    1. WHO: TAG-VE statement on the meeting of 3 January on the COVID-19 situation in China. In.: World health Organization; 2023.
    1. Hachmann NP, Miller J, Collier AY, Barouch DH. Neutralization Escape by SARS-CoV-2 Omicron Subvariant BA.4.6. N Engl J Med. 2022;387(20):1904–1906. doi: 10.1056/NEJMc2212117.
    1. Wang Q, Li Z, Ho J, Guo Y, Yeh AY, Mohri H, et al. Resistance of SARS-CoV-2 omicron subvariant BA.4.6 to antibody neutralisation. Lancet Infect Dis. 2022;22(12):1666–1668. doi: 10.1016/S1473-3099(22)00694-6.
    1. Qu P, Evans JP, Faraone JN, Zheng YM, Carlin C, Anghelina M, et al. Enhanced neutralization resistance of SARS-CoV-2 Omicron subvariants BQ.1, BQ.1.1, BA.4.6, BF.7, and BA.2.75.2. Cell Host Microbe. 2022 doi: 10.1016/j.chom.2022.11.012.
    1. Liu Y, Rocklov J. The reproductive number of the Delta variant of SARS-CoV-2 is far higher compared to the ancestral SARS-CoV-2 virus. J Travel Med. 2021;28(7) doi: 10.1093/jtm/taab124.
    1. Liu Y, Rocklov J. The effective reproductive number of the Omicron variant of SARS-CoV-2 is several times relative to Delta. J Travel Med. 2022;29(3) doi: 10.1093/jtm/taac037.
    1. Dyer O. Covid-19: China stops counting cases as models predict a million or more deaths. BMJ. 2023;380:2. doi: 10.1136/bmj.p2.
    1. Mission EC: China's Fight against COVID-19: Facts and Figures. In. Mission of the People's Republic of China to the European Union; 2023.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera